Table 1.
Patient demographics.
| Women | Characteristics in women stratified into FMI tertiles | Men | Characteristics in men stratified into FMI tertiles | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| FMI < 10.9 | 10.9 ≤ FMI < 15.4 | FMI > 15.4 | P Value | FMI < 7.6 | 7.6 ≤ FMI < 10.9 | FMI > 10.9 | P Value | |||
| Number, n | 82 | 27 | 28 | 27 | 69 | 23 | 23 | 23 | ||
| Age* | 46 (19–79) | 45 (20–74) | 48 (23–79) | 48 (19–67) | 0.60 | 52 (18–80) | 55 (23–78) | 52 (23–80) | 50 (18–78) | 0.42 |
| Age of onset of asthma* | 20 (2–73) | 20 (1–58) | 21 (1–73) | 21 (1–46) | 0.99 | 28 (2–79) | 24 (1–58) | 31 (1–79) | 30 (1–75) | 0.53 |
| Disease duration yrs | 26 (2) | 24 (3) | 27 (3) | 27 (3) | 0.71 | 24 (2) | 31 (4) | 20 (4) | 20 (3) | 0.06 |
| Never smokers % | 85 | 82 | 89 | 85 | 0.71 | 84 | 78 | 96 | 78 | 0.18 |
| Pack year history | 4 (1) | 6 (3) | 3 (1) | 3 (1) | 0.39 | 6 (2) | 6 (2) | 3 (2) | 9 (6) | 0.39 |
| Positive atopy status % | 68 | 76 | 61 | 69 | 0.07 | 66 | 65 | 77 | 55 | 0.07 |
| Exacerbation rate in previous yr | 4.3 (0.4) | 4.5 (0.6) | 4.0 (0.6) | 4.4 (0.8) | 0.87 | 3.5 (0.4) | 3.5 (0.7) | 3.6 (0.7) | 3.3 (0.7) | 0.96 |
| Maintenance prednisolone % | 51 | 52 | 54 | 48 | 0.69 | 48 | 52 | 39 | 52 | 0.10 |
| Prednisolone dose mg* | 11 (5–40) | 14 (5–40) | 9 (5–15) | 12 (5–23) | 0.20 | 11 (5–20) | 11 (5–20) | 13 (5–20) | 11 (5–20) | 0.46 |
| Inhaled corticosteroid % | 100 | 100 | 100 | 100 | 1.00 | 100 | 100 | 100 | 100 | 1.00 |
| Inhaled corticosteroid dose μg | 1490 (89) | 1427 (150) | 1393 (117) | 1652 (189) | 0.44 | 1547 (86) | 1530 (158) | 1539 (130) | 1648 (84) | 0.83 |
| Long-acting beta agonist % | 90 | 83 | 93 | 92 | 0.62 | 93 | 91 | 91 | 96 | 0.90 |
| Total IgE (kU/L) | 504 (118) | 835 (286) | 309 (134) | 374 (190) | 0.14 | 644 (132) | 638 (293) | 770 (198) | 523 (189) | 0.75 |
| FEV1 % predicted# | 81 (2) | 88 (4) | 76 (4) | 79 (4) | 0.08 | 73 (3) | 73 (4) | 69 (5) | 76 (5) | 0.60 |
| FEV1 / FVC# (%) | 74 (1) | 77 (2) | 72 (2) | 74 (2) | 0.18 | 67 (2) | 65 (3) | 65 (3) | 71 (2) | 0.23 |
| FENO ¶ (ppb) | 32 (24–42) | 32 (21–51) | 30 (15–58) | 33 (20–53) | 0.99 | 34 (26–43) | 26 (16–41) | 37 (21–65) | 41 (28–59) | 0.39 |
| Sputum eosinophil count¶ (%) | 5 (3–7) | 3 (1–9) | 6 (3–14) | 6 (3–11) | 0.31 | 5 (3–7) | 5 (3–9) | 5 (2–11) | 5 (2–10) | 0.72 |
| Sputum neutrophil count (%) | 55 (3) | 51 (6) | 60 (5) | 55 (5) | 0.48 | 59 (3) | 58 (6) | 59 (5) | 62 (5) | 0.88 |
| JACQ score | 2.4 (0.1) | 2.4 (0.3) | 2.5 (0.2) | 2.4 (0.3) | 0.92 | 2.2 (0.2) | 1.5 (0.2) | 2.3 (0.3) | 2.7 (0.2) | <0.001 |
| JACQ score(independent of FEV1 ) | 2.3 (0.2) | 2.4 (0.3) | 2.4 (0.2) | 2.3 (0.3) | 0.97 | 2.0 (0.2) | 1.2 (0.2) | 2.0 (0.3) | 2.7 (0.2) | 0.01 |
| BMI (kg/m2) | 30.0 (0.7) | 23.2 (0.5) | 30.1 (0.6) | 36.7 (1.0) | <0.001 | 29 (1) | 23.7 (0.6) | 27.4 (0.6) | 36.0 (1.1) | <0.001 |
| FMI (kg/m2) | 13.3 (0.6) | 7.9 (0.4) | 13.5 (0.4) | 18.6 (0.7) | <0.001 | 10 (0.5) | 6.1 (0.3) | 8.9 (0.3) | 14.2 (0.6) | <0.001 |
Data presented as mean (SEM) unless otherwise stated. *Mean [range]; BDP equivalent. FEV1: forced expiratory volume in 1 second, FVC: forced vital capacity, FENO: fraction of exhaled nitric oxide, JACQ: Juniper asthma control questionnaire score, BMI: body mass index, FMI: fat mass index. Data presented as mean (SEM) unless otherwise stated; #postbronchodilator; ¶geometric mean (95% CI).